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ocdem.ox.ac.ukAbstractContext: Up to 3% of US and UK populations are prescribed glucocorticoids (GC). Suppression of the hypothalamo–pituitary–
adrenal axis with the potential risk of adrenal crisis is a recognized complication of therapy. The 250 mg short Synacthen
stimulation test (SST) is the most commonly used dynamic assessment to diagnose adrenal insufficiency. There are challenges
to the use of the SST in routine clinical practice, including both the staff and time constraints and a significant recent increase
in Synacthen cost.
Methods: We performed a retrospective analysis to determine the prevalence of adrenal suppression due to prescribed GCs
and the utility of a morning serum cortisol for rapid assessment of adrenal reserve in the routine clinical setting.
Results: In total, 2773 patients underwent 3603 SSTs in a large secondary/tertiary centre between 2008 and 2013 and 17.9%
(nZ496) failed the SST. Of 404 patients taking oral, topical, intranasal or inhaled GC therapy for non-endocrine conditions,
33.2% (nZ134) had a subnormal SST response. In patients taking inhaled GCs without additional GC therapy, 20.5% (34/166)
failed an SST and suppression of adrenal function increased in a dose-dependent fashion. Using receiver operating
characteristic curve analysis in patients currently taking inhaled GCs, a basal cortisolR348 nmol/l provided 100% specificity
for passing the SST; a cortisol value!34 nmol/l had 100% sensitivity for SST failure. Using these cut-offs, 50% (nZ83) of SSTs
performed on patients prescribed inhaled GCs were unnecessary.
Conclusion: Adrenal suppression due to GC treatment, particularly inhaled GCs, is common. A basal serum cortisol
concentration has utility in helping determine which patients should undergo dynamic assessment of adrenal function.ice
.0 UEuropean Journal of
Endocrinology
(2015) 173, 633–642IntroductionGlucocorticoids (GC) have a diverse array of functions
affecting every tissue in the body. GCs are essential for life,
and both excess and deficiency are associated with
increased mortality (1, 2). In patients with an intacthypothalamo–pituitary–adrenal (HPA) axis, endogenous
secretion of cortisol from the adrenal cortex is under the
control of adrenocorticotropic hormone (ACTH) from the
anterior pituitary (3, 4). The dynamic function of the HPAnsed under a Creative Commons
nported License.
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173 :5 634axis is most frequently assessed in clinical practice using
the 250 mg short Synacthen (corticotropin) stimulation
test (SST). The SST has been validated against the gold
standard of insulin-induced hypoglycaemia to provide an
accurate reflection of adrenal cortisol reserve (5), therefore
representing the most widely used tool for diagnosing
adrenal insufficiency. There are significant challenges to
the use of the SST in clinical practice. These challenges
include both the staff and time needed to perform the SST,
a well-documented recent (2014) shortage of Synacthen
and a subsequent significant increase in Synacthen cost.
Endocrine diseases affecting the adrenal or pituitary
gland are important causes of primary and secondary
causes of adrenal insufficiency respectively (6). However,
prescribed GCs can also cause long-term suppression of
the HPA axis and, consequently, adrenal atrophy and an
inability to mount an adequate cortisol response to stress,
rendering patients at an increased risk of adrenal crisis.
Adrenal crisis is a medical emergency necessitating
hospital admission, resuscitation with i.v. fluids and
parenteral GC treatment, and is associated with increased
mortality and a poor outcome (7, 8).
The therapeutic indications and clinical benefit
associated with GC treatment prescribed for underlying
inflammatory conditions are not in doubt. Estimates
suggest that up to 3% of the population of the UK and
USA are currently taking GC therapy (9, 10). Long-term
prescription rates for oral GCs have increased, as has the
use of inhaled GC therapy (11). In the majority of cases,
the doses of prescribed GCs are sufficient to cause HPA axis
suppression (total daily doses O5 mg prednisolone or
equivalent) (10). GC prescriptions are often extended for a
sustained period of time with a median duration in excess
of 4 years; in 25% of the cases, treatment extends beyond
5 years (9). As a result, suppression of the HPA axis may be
frequent and potentially overlooked. Dynamic assessment
of the HPA axis using the SST has not been widely reported
in the literature in the setting of iatrogenic adrenal
suppression. Furthermore, the decision to undertake
dynamic HPA axis testing in patients taking prescribed
GCs is often based upon the presence of symptoms that
may be suggestive of adrenal insufficiency, but these can
be vague and often non-specific (12). Importantly, there
are currently no published data to help guide the clinician
to decide in which patients to undertake assessment of
adrenal cortisol reserve. We can assume that people taking
a regular dose of 5 mg of prednisolone (or equivalent) have
compromised adrenal reserve; however, the degree of HPA
axis suppression in persons taking inhaled, topical or
intra-articular GCs is unknown.www.eje-online.orgWe have performed a detailed retrospective analysis
over a 5-year period in a secondary/tertiary care centre.
Firstly, we have aimed to determine the prevalence of
adrenal insufficiency in patients undergoing SSTs across
all medical specialties, and specifically the prevalence of
adrenal insufficiency due to prescribed GCs. Secondly, we
have analysed whether a morning serum cortisol can
guide the clinician as to which patients are likely to have
an intact HPA axis, and thus to rationalize further
investigation and management.Methods
We retrospectively analysed the results of SSTs performed
in 2773 patients from the electronicmedical record system
at the Queen Elizabeth Hospital, University Hospitals
Birmingham NHS Foundation Trust, UK. All SSTs were
performed in the morning (0900–1200 h), between
1/1/2008 and 31/12/2012 across all specialties in a single
large secondary/tertiary care centre in the UK. An i.m.
administration of synthetic ACTH [1–24] was used
(Synacthen 250 mg, Alliance Pharmaceuticals, Chippen-
ham, UK). In patients treated with oral GCs, these were
suspended for 24-h prior to testing. For patients with acute
pituitary insult (surgery or apoplexy), the SST was delayed
for a minimum of at least 4 weeks after surgery or
presentation, as earlier assessment can result in false
positive passes, since adrenal atrophy only develops
4 weeks after the insult (13). Clinical characteristics of
individuals were recorded, including age, sex, indication
for the SST and the use of GC medication (including dose
and route of administration). Patients on GC replacement
therapy as a consequence of adrenal or pituitary disease
were classified according to their underlying endocrine
condition rather than in groups associated with GC
administration. Similarly, patients with CNS disease
(including tumours) were classified separately from those
prescribed GC therapy due to the potential for the
underlying disease process to impact upon endogenous
HPA axis function. Serum cortisol was analysed on a
standard automated competitive immunoassay platform
(RocheModular system, Roche) where there is no evidence
for cross-reactivity with commonly prescribed inhaled
GCs (14). The inter-assay imprecision was !8% for levels
between 76 and 925 nmol/l. The basal and stimulated
30-min cortisol samples were analysed in a single batch.
Using data from a healthy control population (15) and the
same cortisol assay, a 30-min cortisol ofR550 nmol/l was
regarded as demonstrating a satisfactory adrenal reserve
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173 :5 635and designated a ‘pass’, whereas a 30-min value of
!550 nmol/l was designated a ‘fail’.Statistical analysis
Results are expressed as meansGS.D. for parametric data
and medians and inter-quartile ranges for non-parametric
data. For comparison of single variables, t-tests have been
used (or non-parametric equivalents) with paired analysis
where appropriate. For analyses involving multiple
comparisons, one-way ANOVA with Bonferroni’s multiple
comparison post-hoc correction or, for non-parametric
data, Kruskal–Wallis with Dunn’s multiple correction tests
were used to determine statistical significance. Two-tailed
significance was set at P!0.05. For comparison of the
prevalence of SST failure/pass, c2 analysis was used. To
analyse basal cortisol as a predictor of passing the SST,
receiver operator characteristic (ROC) curves were gener-
ated with true positive results (sensitivity) plotted against
false positive (1-specificity). Area under the curve (AUC) of
a ROC curve indicates the ability to discriminate a true
result, with values of 0.5 showing no discrimination and
values of 1.0 equal to perfect discrimination. The ‘best fit’
value of the curve was determined using the Youden index
(threshold value for which (SensitivityCSpecificityK100)
is maximized). We performed sub-group analysis in the
following categories: age, sex (including pre and post-
menopause), pituitary disease and inhaled GCs. To
determine if the inclusion of repeat tests would influence
the discriminatory value of a morning cortisol to predict
adrenal reserve, a further analysis including the entireTable 1 The results of SSTs in 2773 patients divided according to
Description of indication
1 Treatment with inhaled, intra-nasal or topical glucocorticoid
2 Treatment with oral or i.v. glucocorticoids
3 Post-operative assessment after pituitary surgery (without
radiotherapy)
4 Post-operative assessment after pituitary surgery (with radiot
5 Pituitary adenoma (without surgery or radiotherapy)
6 Other conditions affecting the pituitary
7 Other tumours of the CNS
8 Adrenal disease (CAH, Addison’s disease, adenoma, carcinom
9 Co-existent autoimmune disease (thyroid disease, type 1 dia
mellitus, premature ovarian failure, vitiligo)
10 Hyponatraemia or hyperkalaemia
11 Hypoglycaemia
12 Hypotension, syncope, collapse
13 Fatigue, weight loss, malaise
14 Other indications, including critical care admission or not spcohort of all 3603 SSTs was performed (see Supplementary
Table 1, see section on supplementary data given at the
end of this article). Statistical analysis was performed using
the GraphPad Prism 6.0 software package (GraphPad
Software, Inc. La Jolla, CA, USA).Results
Overall, 496 patients (17.9%) failed the SST (Table 1).
In cases where the SST had been performed without a
confirmed endocrine diagnosis, or in patients not receiv-
ing GC therapy, failure rates were low (0–8.8%).Adrenal suppression due to prescribed GCs
In total, 404 SSTs were performed to determine adrenal
reserve in patients who had been prescribed GC therapy
(indications 1 and 2 of Table 1). The prevalence of SST
failure in this cohort was 33.2% (134/404). Patients with
pituitary, adrenal and CNS disease (indications 3–8 from
Table 1) were then excluded. Patients were further
subdivided based upon their GC therapy status: those
currently taking GCs and those previously exposed to GC
therapy (Table 2). Data were compared against individuals
who were GC naı¨ve and without established endocrine
or CNS disease (nZ1287). In GC-naı¨ve patients, 7.5%
(96/1287) failed the SST. A similar SST failure rate was
observed for those patients previously exposed to GC
therapy (10.9% (7/64)). However, failure rates were
significantly higher in patients currently taking GC
therapy (37.4% (127/340) c2 analysis, P!0.05). In patientsindication.
Total (n) % Pass (n) % Fail (n)
s 228 75.4 (172) 24.6 (56)
176 55.7 (98) 44.3 (78)
195 70.3 (137) 29.7 (58)
herapy) 59 71.2 (42) 28.8 (17)
264 89.8 (237) 10.2 (27)
175 77.1 (135) 22.9 (40)
315 74.9 (236) 25.1 (79)
a) 74 39.2 (29) 60.8 (45)
betes 113 92.0 (104) 8.0 (9)
68 91.2 (62) 8.8 (6)
32 100 (32) 0 (0)
173 96.0 (166) 4.0 (7)
178 92.7 (165) 7.3 (13)
ecified 723 91.6 (662) 8.4 (61)
2773 82.1% (2277) 17.9% (496)
www.eje-online.org
Table 2 The impact of glucocorticoid therapy status upon SSTresults. Indications are as follows: (1) treatment with inhaled, nasal or
topical glucocorticoids; (2) treatment with i.v. or oral glucocorticoids; (3) post-operative assessment after pituitary surgery (without
radiotherapy); (4) post-operative assessment after pituitary surgery (with radiotherapy); (5) pituitary adenoma (without surgery or
radiotherapy); (6) other conditions affecting the pituitary; (7) other tumours of the CNS; (8) Adrenal disease (CAH, Addison’s disease,
adenoma, carcinoma); (9) co-existent autoimmune disease (thyroid disease, type 1 diabetes mellitus, premature ovarian failure,
vitiligo); (10) hyponatremia or hyperkalaemia; (11) hypoglycaemia; (12) hypotension, syncope, collapse; (13) fatigue, weight loss,
malaise; and (14) other indications, including critical care admission or not specified.
Indication
Glucocorticoid naive Previous glucocorticoid therapy Current glucocorticoid therapy
n % Pass (n) % Fail (n) n % Pass (n) % Fail (n) n % Pass (n) % Fail (n)
1 0 0 0 13 84.6 (11) 15.4 (2) 215 74.9 (161) 25.1 (54)
2 0 0 0 51 90.2 (46) 9.8 (5) 125 41.6 (52) 58.4 (73)
3 103 89.3 (92) 10.7 (11) 9 100 (9) 0 (0) 83 43.4 (36) 56.6 (47)
4 44 86.4 (38) 13.6 (6) 2 100 (2) 0 (0) 13 15.4 (2) 84.6 (11)
5 238 95.0 (226) 5.0 (12) 3 33.3 (1) 66.7 (2) 23 43.5 (10) 56.5 (13)
6 132 93.2 (123) 6.8 (9) 1 100 (1) 0 (0) 42 26.2 (11) 73.8 (31)
7 222 95.0 (211) 5.0 (11) 18 83.3 (15) 16.7 (3) 75 13.3 (10) 86.7 (65)
8 34 76.5 (26) 23.5 (8) 0 0 0 40 7.5 (3) 92.5 (37)
9 113 92.0 (104) 8.0 (9) 0 0 0 0 0 0
10 68 91.2 (62) 8.8 (6) 0 0 0 0 0 0
11 32 100 (32) 0 (0) 0 0 0 0 0 0
12 173 96.0 (166) 4.0 (7) 0 0 0 0 0 0
13 178 92.7 (165) 7.3 (13) 0 0 0 0 0 0
14 723 91.6 (662) 8.4 (61) 0 0 0 0 0 0
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173 :5 636currently taking prescribed GCs, failure rates were highest
in those patients taking oral therapy (58.4% (73/125),
P!0.01).HPA axis suppression and inhaled GCs
SST failure remained high in patients currently prescribed
inhaled GC or topical GC therapy compared to GC-naı¨ve
patients (Fig. 1). In patients taking inhaled GCs without
additional GC therapy, 34 of 166 patients failed the SST
(20.5%). SST failure rates were 21.2% (22/104) for patients
taking fluticasone, 16.7% (6/36) for beclometasone, 19.1%
(4/21) for budesonide and 2/5 on ciclesonide. Where doses
were recorded (beclometasoneZ28, or fluticasone nZ79),
the prevalence of SST failure was highest in those patients
taking the largest doses (Fig. 1C and D). The 30-min serum
cortisol levels were significantly lower in patients on the
highest doses of both beclometasone and fluticasone in
comparison with those patients on lower doses (Fig. 1E
and F). Baseline cortisol levels were also suppressed on the
highest doses of fluticasone (461G60 vs 205G49 nmol/l,
P!0.05) (Fig. 1F).
Comparing the SST response between patients taking
beclometasone or fluticasone, 30-min cortisol levels
were not significantly different at the highest doses
of inhaled GCs (445G85 vs 631G98 nmol/l, fluticasone
O500 mg/day vs beclometasone O400 mg/day, PZNS).www.eje-online.orgHowever, at lower doses, fluticasone therapy was associ-
ated with a greater impairment of 30-min cortisol response
(858G70 vs 1229G201 nmol/l, fluticasone !500 mg/day
vs beclometasone !400 mg/day, P!0.05; 740G37 vs
1009G177 nmol/l, fluticasone 500 mg/day vs beclometa-
sone 400 mg/day, P!0.05). There were no significant
differences in clinical characteristics in the patient cohorts
when comparing across prescribed dose of inhaled GCs
between different inhaled GCs or those who failed or
passed the SST (data not shown).Baselinemorning cortisol as a predictor of SSToutcome
Baseline serum cortisol in the cohort of 3606 SSTs (2773
patients) correlated significantly with the levels 30 min
after ACTH stimulation (Sperman’s rZC0.74 P!0.0001).
ROC curve analysis of baseline morning cortisol as a
predictor for passing the SST showed an AUC of 0.91.
Serum cortisol concentration of 506 nmol/l gave 100%
specificity for predicting passing the SST and a serum
cortisol concentration of 107 nmol/l was 99% sensitive for
predicting failure (Table 3). In the 404 patients exposed to
GC therapy, a serum cortisol concentration of 410 nmol/l
gave 100% specificity for predicting passing the SST and
a serum cortisol concentration of 34 nmol/l was 100%
sensitive for predicting failure. Also, 166 SSTs were
performed on patients taking inhaled GCs. All those
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Figure 1
Excluding patients with underlying pituitary, adrenal or CNS
disease, current glucocorticoid therapy is associated with
increased rates of SST failure (A). SST failure is common across
all routes of glucocorticoid administration, although it is most
frequent in patients on oral therapy (B). (*P!0.05, **P!0.01).
The impact of inhaled glucocorticoid therapy on the prevalence
of adrenal suppression (C, D, E and F). Beclometasone and
fluticasone administration cause a dose-dependent increase in
SST failure rates (C and D) and absolute reductions in basal and
30-min cortisol levels after synthetic ACTH1–24 stimulation
(E and F) (basal serum cortisolZblack bars, 30-min cortisolZ
white bars) (*P!0.05 vs lowest daily dose).E
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passed the SST and all those with a baseline serum cortisol
concentration of 34 nmol/l or lower failed the SST (Table 3
and Fig. 2A). Adopting these 100% cut-offs (348 and 34
respectively, 83 SSTs (representing 50% of all SSTs
undertaken in patients on inhaled GCs) need not have
been performed, as the results of the SST could have been
predicted form the morning cortisol result alone (Fig. 2A).Table 3 SST results with AUC, best-fit serum cortisol (max (Sensitivi
cortisol concentrations (nmol/l).
Group AUC Best-fit cortisol (n
All patients (nZ2773) 0.91 (0.89–0.92) 221 (86%sensC77%
All current GC use (nZ404) 0.92 (0.89–0.94) 220 (78%sensC88%
Inhaled GCs (nZ166) 0.90 (0.85–0.95) 308 (70%sensC94%
Oral GCs (nZ143) 0.89 (0.84–0.94) 213 (74%sensC94%The AUC, best-fit cortisol value and cut-off cortisol
values for respective specificities and sensitivities accor-
ding to age, sex, menopausal status and other indications
(including endocrine diagnoses) are presented in Supple-
mentary Table 2, see section on supplementary data given
at the end of this article.Discussion
In this study we have demonstrated a high prevalence of
adrenal insufficiency associated with GC treatment in the
largest cohort described to date, with an alarming
prevalence in those patients taking GC therapy for non-
endocrine disease. Indeed, SST failure rates were higher in
those taking GC therapy than in those with underlying
pituitary disease. GCs are currently prescribed to up to 3%
of the population (9, 10, 11) and there is little doubt that
GC excess is associated with significant adverse effects and
suppression of the HPA axis (16). Furthermore, epidemio-
logical data from general practice records has demon-
strated a link between GC prescriptions and the risk of
cardiovascular events and heart failure (17).
Adrenal suppression is considered unusual where GCs
have been prescribed for!2 weeks (18) but is more likely
following prolonged administration (19). However, a
recent prospective study in patients prescribed high-dose
oral prednisone (40 mg) identified evidence of adrenal
suppression in O60% of patients after 6 days of therapy
(20). Some studies have suggested that adrenal suppres-
sion is not tightly linked to the duration and dose of oral
GCs (16, 21); however, this is not the case in all studies
(22) and this may well reflect inter-individual variability
in GC action and metabolism, including the activity of
CYP3A4, the major pathway for the inactivation of most
prescribed GCs (23, 24, 25, 26).
Within our cohort, more than 20% of patients taking
prescribed inhaled GCs failed the SST, which is consistent
with somebutnot all of thepublished literature (27, 28, 29).
Thevariability in resultsmay reflect theuseof inappropriatetyCSpecificityK100)) and sensitivities and specificities for serum
mol/l)
Specificity (%) Sensitivity (%)
95 99 100 95 99 100
spec) 347 461 506 164 107 !20
spec) 331 386 410 168 63 34
spec) 342 347 348 146 62 34
spec) 383 405 413 198 115 114
www.eje-online.org
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Figure 2
Baseline serum cortisol as a predictor of 30-min cortisol levels
during an SST. Baseline serum cortisol is graphed against the %
likelihood of passing (specificityZcontinuous line) or failing
(sensitivityZdashed line) the SST. (A) Inhaled glucocorticoids.
(B) Oral glucocorticoids.
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including SSTs; isolatedmeasurements of serumcortisol are
difficult to interpret and can be misleading. We and others
have previously documented the prevalence of adrenal
insufficiency in relatively small cohorts of patients (nZ33)
taking inhaled GCs for respiratory disease and demon-
strated SST failure rates of up to 48% (30).
Our data have shown a dose dependency in the SST
response with inhaled GCs and are in agreement with
evidence from the published literature suggesting that
adrenal suppression is most frequent at the highest doses
of inhaled GCs (31), although we did observe suppression
in some patients taking lower doses. In addition, it is
important to recognize that adrenal suppression can persist
for prolonged periods after discontinuation of GC therapy
(32). Whilst we have been able to demonstrate the
magnitude of a clinical problem that is more extensive
than iswidely appreciated, it is fundamentally important to
understand its clinical consequences. Current clinical data
in this regard are lacking. We have previously shown that
decreased adrenal reserve as a consequence of inhaled GCs
is associated with reduced quality of life in patients with
bronchiectasis (30) and the use of inhaled GCs in patients
with chronic obstructive pulmonary disease (COPD) is
knownto increase the riskof type2diabetesandpneumonia
(11, 33). In the setting of intensive care, a significant
proportionofpatientshave functional adrenal insufficiency
and this has been associated with a poorer outcome (34).
Taken together, these observations raise the intriguing
possibility that poor clinical outcome inpatients on inhaled
GCs may be due at least in part to HPA axis suppression,
adrenal insufficiency and the consequent inability to
mount an adequate cortisol stress response, and this haswww.eje-online.orgsignificant implications for the therapeutic approach to
these patients (Supplementary Table 3 and Supplementary
Figure 1, see section on supplementary data).
Routine screening for adrenal insufficiency in the
context of inhaled GCs is not currently recommended.
The magnitude of the clinical problem may be daunting,
and making a case for routine assessment of HPA axis
function in all patients on inhaled GCsmay be prohibitive
considering the workload and cost implications. To date,
dynamic stimulation tests such as the SST and the ITT are
considered mandatory for reliable investigation of adrenal
reserve (13, 35, 36). The utility of a basal cortisol in
predicting adrenal reserve has been examined previously
(37, 38). Using a single morning cortisol as the first
screening step has the potential, in some circumstances, to
reduce the need for dynamic tests and as a consequence to
decrease cost and workload and reduce unnecessary tests
for patients. In addition, the recent well-publicized world-
wide shortage of Synacthen has highlighted the role that
alternative assessments of HPA axis function may play.
A baseline cortisol result below 100 nmol/l is considered
highly indicative of adrenal insufficiency (37, 39),
although this is not universally accepted (35, 40). Different
basal cortisol levels, ranging from 285 to 500 nmol/l, have
been proposed as predictive of adequate adrenal reserve
(35, 37, 39, 40, 41, 42, 43). However, these studies have
been small (nZ197, 761, 68, 679, 210, 54 and 166
respectively) and in many cases have not been able to
systematically examine variable cortisol level cut-offs or
determine the impact of underlying aetiology and
specifically the clinical problem of iatrogenic adrenal
insufficiency. Through our systematic approach to asses-
sing adrenal function in a large cohort of patients, we are
now able to propose an algorithm (Fig. 3) that is likely to
have significant clinical utility and is safe. In patients
prescribed inhaled GCs and in the absence of symptoms of
adrenal insufficiency, we recommend measuring annual
baseline serum cortisol concentrations as a useful tool in
assessing adrenal GC reserve. A baseline serum cortisol
O348 nmol/l is suggestive of an intact adrenal response to
stress. A baseline cortisol of!35 nmol/l suggests the need
for physiological oral hydrocortisone replacement and, if
possible, a reduction in inhaled GC doses. Baseline serum
cortisol concentrations between 35 and 348 nmol/l
suggest the need for further investigation, including an
SST and possible oral GC replacement. We deliberately
identified a cut-off with 100% specificity such that we can
be confident not to miss unrecognized adrenal insuffi-
ciency. Adopting this algorithm would mean that 50% of
the SSTs on patients taking inhaled GCs need not have
Clinical suspicion of adrenal insufficiency 
Consider annual baseline cortisol for patients on high dose inhaled glucocorticoids 
Random serum cortisol (0900–1100 h)
(continue inhaled glucocorticoids) 
Cortisol 35–348 (nmol/l)
( 29/83 failed SST) 
Cortisol ≥348 (nmol/l)
(0/78 failed SST) 
SST need not be performed 
No need for oral glucocorticoid 
replacement  therapy 
If symptoms of adrenal 
insufficiency present, consider 
SST. 
Cortisol <35  (nmol/l)
(5/5 failed SST) 
Needs confirmatory SST 
Combined respiratory and endocrine 
management to rationalise inhaled 
glucocorticoids where possible 
If fails SST consider oral steroid 
replacement and need for 
increased dose during inter-current 
illness 
Repeat testing in 3–6 months 
SST need not be performed 
Combined respiratory and endocrine 
management to rationalise inhaled 
glucocorticoids where possible 
Consider oral steroid replacement 
and need for increased dose 
during inter-current illness 
Repeat testing in 3–6 months 
Figure 3
Putative algorithm to aid in the rationalization of assessment of the HPA axis in patients taking inhaled glucocorticoids.
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patients with underlying adrenal or pituitary pathology,
limiting unnecessary test and the potential for significant
cost savings.
The management of patients with adrenal insuffi-
ciency in the context of endocrine disease has been
reviewed extensively (6). However, there are currently no
guidelines or published studies that have determined the
optimal management strategy for those patients with
adrenal insufficiency due to prescribed GCs. For those on
oral therapy, continuation of treatment as clinically
indicated is appropriate, followed by weaning of the
dose if the duration has been longer than 2 weeks. Once
the daily doses have been reduced to those approaching
physiological levels (equivalent of prednisolone
5 mg/day), and assuming that GC therapy is no longer
indicated for their initial prescribed purpose, an SSTshould be performed and, if passed, the GCs can be safely
stopped. If, however, the SST is failed, we would normally
initiate hydrocortisone replacement therapy with appro-
priate ‘sick day rules’ with regards to increasing dose at
times of stress or inter-current illness, provide the patient
with information and a ‘steroid card’ and perform repeat
testing after 3–6 months.
For those patients taking inhaled GCs, the situation
is more complex, as the inhaled GC cannot provide the
adequate systemic actions that are needed at times of
stress. A combined respiratory and endocrinology
approach is appropriate. If possible, inhaled GC doses
may be reduced, but this will be entirely dependent upon
the underlying respiratory condition. For those patients
who fail the SST, we would advocate daily hydrocortisone
replacement (including advice with regards to ‘sick day
rules’ and provision of an emergency ‘steroid card’ aswww.eje-online.org
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173 :5 640described above). Repeat SST should be performed,
especially if modification to the inhaled GC therapy
has been undertaken to assess the potential return of
HPA axis function.
There are limitations with the current analysis,
although it does represent a cross-sectional analysis of
unselected clinical data across all medical specialties.
The data are retrospective and the decision to perform
the SST was based on clinical indication as assessed
by the individual clinician leading to a potential positive
selection bias that may overestimate prevalence rates.
Duration of GC treatment is likely to be important, as is
the length of time since cessation of GC therapy. However,
data from our electronic patient records does not allow
accurate assessments of the duration of therapy or the
time since therapy had been discontinued. The cut-off
levels in this paper relate specifically to the assay used, and
interpretation of these data should be made in the context
of local cortisol assays as well as the methodology for the
SST (i.m. vs i.v. Synacthen and 30 vs 60 min cortisol
values). We advocate utilising the i.m. high dose
Synacthen test, as it performs well in clinical practise
(13, 44) and has been validated against the gold standard
(insulin-induced hypoglycaemia) (5). In addition, robust
longitudinal clinical outcome data was not available from
our electronic database, which is of fundamental
importance.
The SST failure rate in GC-naı¨ve patients without
established endocrine or CNS disease was higher than
might have been expected (7.5%). The explanation for this
is not clear and may relate to new diagnoses of endocrine
(or other, e.g. malignancy) disease that had not been fully
investigated prior to the SST being requested, although the
aetiology in many remains unexplained. Importantly,
some of these tests were performed in the intensive care
setting where the underpinning mechanisms causing
compromised adrenal reserve are still unknown.
In summary, the prevalence of adrenal insufficiency
due to prescribed GCs is high and almost certainly
represents the commonest cause of compromised adrenal
function. Importantly, we have highlighted the potent,
dose-dependent ability of inhaled GCs to suppress
endogenous HPA axis function, and identified the utility
of a morning cortisol level in guiding the clinician as to
which patients may need dynamic assessment of
adrenal reserve. Futures prospective studies are needed to
accurately define the clinical consequences of adrenal
suppression for patients prescribed inhaled GC therapy
and determine the optimal medical management for
these patients.www.eje-online.orgSupplementary data
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